The COVID- 19 pandemic is proving to be the worst health catastrophe of this century so far: Its spread is having very significant effects not only on health, with a high number of deaths and infected patients, but also on the global economy, with rising unemployment and increased poverty; it also brought psychological implications, because of a high increase in cases of post-traumatic stress syndrome \[[@bib0005]\]. These effects were immediately evident in Lombardy, which is the Italian region most affected by the outbreak.

The seriousness of the pandemic immediately highlighted among those who had decision-making roles how its management should be approached according to the principles of crisis management.

Crisis management is the process by which an organisation manages a disruptive and unexpected event that threatens to damage the organisation or the parties concerned \[[@bib0010]\].

Three elements are common to a crisis: (a) a threat to the organisation, (b) the surprise element, and (c) a short decision time.

Management requires on the one hand the ability to make quick decisions; on the other hand the search and application of different organizational models compared to those previously applied.

In Italy, on February 20, 2020, a 38-year-old man was admitted with acute respiratory insufficiency to the intensive care unit (ICU) of the Codogno Hospital, a small town in Lombardy nearby Milan, marking the beginning of the SARS-CoV2 epidemic in Italy. The sudden massive inflow of patients overwhelmed existing protocols in place to handle rapidly evolving emergency situations. In order to adequately respond to the quick and wide spreading of the SARS-CoV2 infection, hospitals needed new strategic organisational planning.

Hospitals had to quickly change their patient management skills by reviewing their organisation across all sectors \[[@bib0015]\]. Intensive care and sub intensive care beds for patients with respiratory problems had to be increased \[[@bib0020]\]**.** All hospitalisations for non-urgent patients not infected by SARS-CoV2 had to be suspended and essentially all medical and nursing staff were involved in the management of patients affected by COVID-19.

In parallel with the review of the organisational aspects, the research sector also had to change its approach, especially by accelerating planning of clinical trials and their authorisation phases, and in the request for informed consent.

Especially at the beginning it was of fundamental importance to concentrate efforts to increase the diagnostic, etio-pathogenic and therapeutic knowledge of the virus. All this has seen a huge effort also by researchers. Despite the emergency, some fundamental concepts were reiterated for the respect of the cardinal principles of scientific research.

The European Medicines Agency through its Committee for Medicinal Products for Human Use *"is concerned about the amount of planned small studies or compassionate use programmes across Europe that are unlikely to be able to generate the required level of evidence to allow clear-cut recommendations. Such studies would not be in the best interests of patients. Multi-arm clinical trials investigating different agents simultaneously have the potential to deliver results as rapidly as possible across a range of therapeutic options according to the same evaluation criteria. This concept has been developed for COVID-19 by institutions in the EU and by WHO and is generally supported. It would be important that all EU countries are considered for inclusion in such trials*" \[[@bib0025]\]

The Italian National Institute of Health (Istituto Superiore di Sanità -- I.S.S.) recommended that *"it is indeed crucial to collect and store the biological materials of the population concerned according to the established international criteria and in compliance both with ELSI (ethical - legal - social) requirements and the rights of the patients involved, in order to make them available over time for collaborative research projects. In this perspective, it is recommended to keep the collections of COVID-19 samples in biobanks which, as an entity recognised by the competent authorities, must ensure and manage, according to proven quality standards and in a stable and continuous manner, the collection, preparation, storage and distribution of samples and related information for future research and/or diagnosis."* \[[@bib0030]\]

As for the collection of informed consent from each patient, while reiterating its obligatory nature, novel approaches were devised in Italy in order to enable the researchers to proceed quickly in the collection of information useful for scientific research, such as the use of verbal authorisation made by the patient in front of witnesses or in case this was not possible authorisation granted by the patient after the conditional collection of biological samples.

Italy also adopted temporary regulatory changes during the pandemic period, on the one hand to speed up the approval of clinical studies, on the other to coordinate them.

The Italian Medicines Agency (Agenzia Italiana del Farmaco -- AIFA) adopted extraordinary and simplified procedures for the presentation and approval of the trials and for the definition of the methods for joining the studies and acquiring data.

The Ethics Committee of the National Institute for Infectious Diseases Lazzaro Spallanzani in Rome was identified as the only national ethics committee for the evaluation of clinical trials of medicines for human use and medical devices for patients with COVID-19.

The request and authorisation to import drugs for compassionate and off-label use was also simplified and speeded up.

In conclusion, scientific research and clinical trials must go hand in hand with clinical-assistance activities, even more during a pandemic period; these aspects are of great importance for those who have managerial and decision-making tasks, they are useful for scientific progress and health management and, in cases like COVID\'s, help to limit the spread of the infection and its consequences on the population. In the present circumstances all this was achieved without forsaking the principles of ethics and transparency that must never be overlooked.
